HL Women Conference 2024
April 2024
The Hogan Lovells Washington, D.C. office is excited to invite you to its inaugural Women's Conference for women partners and counsel in the Americas. This conference is designed to serve...
Hogan Lovells APAC Life Sciences and Health Care Webinar Series - Spotlight on the U.S. - Session 2
18 January 2024 | 10:00 a.m. - 11:00 a.m. (CST)
Webinar No. 2: Life Sciences companies navigating the impact of the U.S. Inflation Reduction Act
Why IP lawyers should care about the IRA
4 May 2023 | 10:30 a.m. - 12:00 p.m. (EDT)
Join the Hogan Lovells Life Sciences & Health Care team and guest speaker Henry Hadad, Senior Vice President and Deputy General Counsel of Bristol Myers Squibb, for a discussion on the...
Boston: Life Sciences and Health Care Horizons 2023
29 March 2023 | 2:00 p.m. - 5:30 p.m. (EST)
Launching successfully in the U.S. and Europe
Biotech Showcase and exclusive reception during the J.P. Morgan 41st Annual Healthcare Conference
9-12 January 2023
On 9-12 January 2023, Hogan Lovells is a sponsor at the Biotech Showcase. Alice Valder Curran, Jodi Scott, and Andrew Strong will present at the conference.
Dinner, drinks, and discussion on the impacts of the Inflation Reduction Act of 2022
01 December 2022 | 05:30 PM - Registration and cocktails | 06:30 PM - Dinner and discussion (EST)
We invite you to a cocktail reception and dinner with the Hogan Lovells Life Sciences and Health Care team on Thursday, December 1 at The Royal Sonesta in Cambridge.
Unpacking the prescription drug provisions of the Inflation Reduction Act of 2022
13 &15 September 2022: 12:00 PM - 1:30 PM EDT | 20 September 2022: 12:00 PM - 1:00 PM EDT
On 7 August, 2022, the Senate passed the proposed Inflation Reduction Act of 2022, which includes a number of significant prescription drug-related provisions. The bill generally revives...
U.S. Market access strategy at the clinical stage for all companies considering a launch: A three-part series
20 April, 4 May, and 18 May 2022
The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the...
